Clarius Ultrasound Scanner
Clarius Mobile Health Corp. • Radiology • 10/05/2023
Device Purpose
The Clarius Ultrasound Scanner PAL HD3 is a portable diagnostic imaging device that utilizes a novel dual-array transducer, integrating both linear and phased array capabilities into a single unit. This system employs piezoelectric technology to generate and receive ultrasound waves, wirelessly transmitting real-time images to standard iOS or Android devices, thereby aiming to improve clinical workflow efficiency across a wide range of medical applications.
Summary
The Clarius Ultrasound Scanner, specifically the PAL HD3 model, is a portable, software-controlled diagnostic ultrasound system designed for acquiring and displaying high-resolution, real-time ultrasound data. It operates using piezoelectric material within its transducer to transmit high-frequency, non-ionizing sound waves into the body and convert returning echoes into electronic signals, forming images that are wirelessly transmitted via Wi-Fi and Bluetooth to a standard iOS or Android device. This system, intended for trained healthcare professionals, facilitates diagnostic imaging in diverse settings, including emergency medical services. The key innovation of the PAL HD3 is its multipurpose dual-array transducer, which integrates high-frequency linear (5-15 MHz) and low-frequency phased (1-5 MHz) array ceramics side-by-side within a single scanner head, offering a wide frequency range (1-15 MHz). This design aims to enhance clinical workflow by allowing practitioners to switch between distinct imaging capabilities for various depths and structures without changing transducers. The PAL HD3 supports multiple imaging modes (B-mode, M-mode, Doppler modalities) for broad diagnostic applications, including ophthalmic, cardiac, abdominal, musculoskeletal imaging, and procedural guidance, with its performance and safety having been verified through non-clinical testing.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the image quality of the PAL HD3's integrated linear and phased arrays compare to using two separate, dedicated L15 HD3 and PA HD3 transducers, particularly at the extremes of their respective frequency ranges?; What is the measured impact on battery life and device temperature when frequently switching between the linear and phased array functionalities within the single PAL HD3 unit during a prolonged examination?; Are there any specific clinical scenarios or anatomical regions where the side-by-side arrangement of the dual arrays in the PAL HD3 might introduce artifacts or limitations compared to single-array transducers?; What is the typical learning curve for clinicians transitioning from using separate transducers to the integrated PAL HD3, especially regarding the switching mechanism and optimizing settings for each array type within the same device?; Beyond workflow efficiency, are there demonstrable improvements in diagnostic accuracy or procedure time for specific applications (e.g., complex multi-organ POCUS exams) with the PAL HD3 compared to using separate transducers?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, ML-BOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly